Patents by Inventor William Sievert
William Sievert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9932646Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: GrantFiled: October 14, 2014Date of Patent: April 3, 2018Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stehpen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman Leipzig, Thomas Bock Tuebingen, William Sievert, Sharon Lewin
-
Patent number: 9702005Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: November 26, 2013Date of Patent: July 11, 2017Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph John Sasadeusz, Peter William Angus, William Sievert
-
Publication number: 20160032410Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: ApplicationFiled: October 14, 2014Publication date: February 4, 2016Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman Leipzig, Thomas Bock Tuebingen, William Sievert, Sharon Lewin
-
Patent number: 8859198Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: GrantFiled: June 4, 2007Date of Patent: October 14, 2014Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman, Thomas Bock, William Sievert, Sharon Lewin
-
Publication number: 20140296504Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: November 26, 2013Publication date: October 2, 2014Applicant: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
-
Patent number: 8592143Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: June 1, 2010Date of Patent: November 26, 2013Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
-
Patent number: 8211633Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: July 9, 2010Date of Patent: July 3, 2012Assignees: Melbourne Health, Austin Health, Southern HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
-
Publication number: 20110189652Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: July 9, 2010Publication date: August 4, 2011Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
-
Patent number: 7989162Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: June 20, 2008Date of Patent: August 2, 2011Assignees: Melbourne Health, Austin Health, Southern HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
-
Patent number: 7846663Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 31, 2007Date of Patent: December 7, 2010Assignees: Melbourne Health, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
-
Publication number: 20100304392Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: June 1, 2010Publication date: December 2, 2010Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
-
Publication number: 20100221746Abstract: The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent. The invention also relates to methods of treatment of disease associated with fibrosis in a vertebrate, as well as methods for diagnosing such conditions, and kits therefor.Type: ApplicationFiled: May 17, 2010Publication date: September 2, 2010Applicants: Inhibin Pty Limited, Monash UniversityInventors: David Phillips, David de Kretser, William Sievert, Shane Patella, Joseph Smolich, David McGaw, Paul Fennessy
-
Patent number: 7745130Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: September 25, 2007Date of Patent: June 29, 2010Assignees: Melborne Health, Austin Health, Southern HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
-
Publication number: 20100075299Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: ApplicationFiled: June 4, 2007Publication date: March 25, 2010Applicants: MELBOURNE HEALTH, AUSTIN HEALTH, BAYSIDE HEALTH, ST.VINCENT'S HOSPITAL (MELBOURNE) LTD. TRADING AS ST. VINCENT'S HOSPITAL MELBOURNE, SOUTHERN HEALTHInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman, Thomas Bock, William Sievert, Sharon Lewin
-
Publication number: 20090226460Abstract: The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent. The invention also relates to methods of treatment of disease associated with fibrosis in a vertebrate, as well as methods for diagnosing such conditions, and kits therefor.Type: ApplicationFiled: March 6, 2009Publication date: September 10, 2009Applicants: Inhibin Pty Limited, Monash UniveristyInventors: David Phillips, David de Kretser, William Sievert, Shane Patella, Joseph Smolich, David McGaw, Paul Fennessy
-
Publication number: 20090081667Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: June 20, 2008Publication date: March 26, 2009Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
-
Publication number: 20090081637Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: September 25, 2007Publication date: March 26, 2009Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
-
Publication number: 20090053201Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: October 31, 2007Publication date: February 26, 2009Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
-
Patent number: 7405039Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: August 4, 2004Date of Patent: July 29, 2008Assignees: Austin Health, Melbourne HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
-
Patent number: 7384747Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: June 24, 2005Date of Patent: June 10, 2008Assignees: Melbourne Health, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert